Meta-Analysis of Efficacy and Safety of Ticagrelor Combined with Rosuvastatin Therapy in the Treatment of Unstable Angina Pectoris

LUO Ruixiang; ZHANG Chen; WU Yang; FAN Zongjing; CUI Jie

doi:10.14009/j.issn.1672-2124.2022.10.020

您当前的位置：

首页 >

文章列表页 >

Meta-Analysis of Efficacy and Safety of Ticagrelor Combined with Rosuvastatin Therapy in the Treatment of Unstable Angina Pectoris

更新时间：2023-04-16

- Meta-Analysis of Efficacy and Safety of Ticagrelor Combined with Rosuvastatin Therapy in the Treatment of Unstable Angina Pectoris
- Vol. 22, Issue 10, Pages: 1244-1250(2022)
- 作者机构：
  
  1. 北京急救中心北区分中心
  2. 北京中医药大学临床医学院
  3. 北京中医药大学东方医院心内科
- 作者简介：
- 基金信息：
- DOI：10.14009/j.issn.1672-2124.2022.10.020
  CLC： R541.4
- Published：2022，
扫描看全文
LUO Ruixiang, ZHANG Chen, WU Yang, et al. Meta-Analysis of Efficacy and Safety of Ticagrelor Combined with Rosuvastatin Therapy in the Treatment of Unstable Angina Pectoris. [J]. 22(10):1244-1250(2022)
DOI：

LUO Ruixiang, ZHANG Chen, WU Yang, et al. Meta-Analysis of Efficacy and Safety of Ticagrelor Combined with Rosuvastatin Therapy in the Treatment of Unstable Angina Pectoris. [J]. 22(10):1244-1250(2022) DOI： 10.14009/j.issn.1672-2124.2022.10.020.

摘要

目的：基于Meta分析，系统评价替格瑞洛联合瑞舒伐他汀治疗不稳定型心绞痛(UAP)的疗效和安全性。方法：计算机检索PubMed、the Cochrane Library、Embase、中国知网、万方数据库及维普数据库，检索时限为建库至2020年9月，筛选有关替格瑞洛联合瑞舒伐他汀治疗UAP的临床随机对照试验(RCT

在常规治疗基础上，研究组患者使用替格瑞洛联合瑞舒伐他汀治疗，对照组患者使用氯吡格雷联合瑞舒伐他汀治疗)。根据纳入和排除标准选取文献、提取数据并进行质量评价，运用RevMan 5.3软件进行Meta分析。结果：共纳入12项RCT

涉及患者1 220例。Meta分析结果显示，与氯吡格雷联合瑞舒伐他汀相比，替格瑞洛联合瑞舒伐他汀治疗UAP患者可明显提高临床总有效率(RR=1.26

95%CI=1.19～1.33

P<0.000 01)及高密度脂蛋白胆固醇水平(MD=0.43

95%CI=0.23～0.63

P<0.000 1)

降低总胆固醇水平(MD=-0.92

95%CI=-1.12～-0.72

P<0.000 01)、三酰甘油水平(MD=-0.75

95%CI=-0.89～-0.61

P<0.000 01)、低密度脂蛋白胆固醇水平(MD=-0.85

95%CI=-1.06～-0.65

P<0.000 01)及超敏C反应蛋白水平(MD=-2.33

95%CI=-2.75～-1.90

P<0.000 01)

减少心绞痛发作频次(MD=-2.94

95%CI=-3.47～-2.40

P<0.000 01)

缩短心绞痛发作持续时间(SMD=-2.35

95%CI=-3.35～-1.35

P<0.000 01)

差异均有统计学意义；两组患者不良反应发生率比较，差异无统计学意义(RR=0.59

95%CI=0.33～1.04

P=0.07)。结论：当前证据表明，替格瑞洛联合瑞舒伐他汀治疗UAP在总有效率及各项临床指标等方面均明显优于氯吡格雷联合瑞舒伐他汀，且安全性与氯吡格雷联合瑞舒伐他汀相当。

Abstract

OBJECTIVE: To systematically evaluate the efficacy and safety of ticagrelor combined with rosuvastatin in the treatment of unstable angina pectoris（UAP）. METHODS: PubMed

the Cochrane Library

Embase

CNKI

Wanfang Data and VIP database were electronically retrieved to collect clinical randomized controlled trial（RCT） of ticagrelor combined with rosuvastatin in the treatment of unstable angina pectoris（on the basis of conventional treatment

the study group was treated with ticagrelor combined with rosuvastatin

while the control group received clopidogrel combined with rosuvastatin）

the retrieval time limit is from the establishment of the database to Sept. 2020. According to the inclusion and exclusion criteria

literature were selected

data were extracted and quality was evaluated. RevMan 5.3 software was used for Meta-analysis. RESULTS: Totally 12 RCT were enrolled

including 1 220 patients. Meta-analysis showed that compared with clopidogrel combined with rosuvastatin

ticagrelor combined with rosuvastatin could significantly improve the total clinical effective rate（RR=1.26

95%CI=1.19-1.33

P<0.000 01） and the level of high density lipoprotein cholesterol（MD=0.43

95%CI=0.23-0.63

P<0.000 1）

decrease the total cholesterol level（MD=-0.92

95%CI=-1.12--0.72

P<0.000 01）

triglyceride level（MD=-0.75

95%CI=-0.89--0.61

P<0.000 01）

low density lipoprotein cholesterol level（MD=-0.85

95%CI=-1.06--0.65

P<0.000 01） and high sensitivity C-reactive protein（MD=-2.33

95%CI=-2.75--1.90

P<0.000 01）

decrease the frequency of angina pectoris（MD=-2.94

95%CI=-3.47--2.40

P<0.000 01）

shorten the duration of angina pectoris（SMD=-2.35

95%CI=-3.35--1.35

P<0.000 01）

with statistically significant differences. There was no statistically significant difference in the incidence of adverse drug reactions between two groups（RR=0.59

95%CI=0.33-1.04

P=0.07）. CONCLUSIONS: Current evidence shows that ticagrelor combined with rosuvastatin in the treatment of UAP is significantly better than clopidogrel combined with rosuvastatin in terms of total effective rate and various clinical indicators

and the safety is similar to that of clopidogrel combined with rosuvastatin.

关键词

不稳定型心绞痛替格瑞洛瑞舒伐他汀Meta分析随机对照试验

Keywords

Unstable angina pectorisTicagrelorRosuvastatinMeta-analysisRandomized controlled trial

references

查看原文

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Systematic Review of Efficacy and Safety of Linezolid in the Treatment of Drug-Resistant Tuberculosis

Systematic Review of Efficacy and Safety of Azelastine Hydrochloride Combined with Mometasone Furoate in the Treatment of Allergic Rhinitis

Systematic Review on Efficacy and Safety of Silybin Capsules in the Treatment of Fatty Liver Disease

Systematic Review on Efficacy and Safety of Mecobalamin Tablets Combined with Mudan Granules in the Treatment of Diabetic Peripheral Neuropathy

Systematic Review of Efficacy and Safety of Montelukast Sodium Tablets Combined with Salmeterol Xinafoate and Fluticasone Propionate Inhalation Aerosol in the Treatment of Moderate and Severe Bronchial Asthma in the Elderly

Related Author

DI Xuan

DONG Yiwen

WANG Weina

LI Xingang

CHEN Di

郑子恢

张亚同

潘慧杰

Related Institution

Dept. of Pharmacy, Beijing Friendship Hospital Affiliated to Capital Medical University

Dept. of Pharmacy, Beijing Hospital

Beijing Hospital

Dept. of Laboratory, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Science

Dept.of Health Service, the Guard Bureau of the Joint Staff Department,Central Military Commission, People’s Republic of China

⁰